Navigation Links
Lilly Caps Successful Year with Strong Fourth-Quarter Results
Date:1/29/2008

resulting from the amortization of the intangible assets acquired in the ICOS acquisition, the impact of foreign exchange rates and production volumes growing at a slower rate than sales, partially offset by manufacturing expenses growing at a slower rate than sales.

Overall, marketing, selling and administrative expenses rose 25 percent, to $6.095 billion. This increase was largely due to the impact of the ICOS acquisition, as well as increased marketing and selling expenses in support of key products, primarily Cymbalta and the diabetes care products, and the impact of foreign exchange rates. Research and development expenses were $3.487 billion, or 19 percent of sales. Compared with 2006, research and development expenses increased 11 percent. In addition to the acquisition of ICOS, this increase was due to increases in discovery research and late-stage clinical trial costs.

Other income decreased by $115.8 million, to $122.0 million, primarily due to the acquisition of ICOS and higher net interest expense, offset in part by higher business development income resulting from out-licensing of development-stage products. Prior to the acquisition of ICOS, the results of the Lilly ICOS joint venture were presented in other income. Subsequent to the acquisition, all sales and expenses associated with Cialis are included in their respective lines on Lilly's income statement.

The reported effective tax rate was 23.8 percent, up from 22.1 percent in 2006.

Full-year 2007 reported net income and earnings per share both increased 11 percent to $2.953 billion and $2.71, respectively, compared with 2006 net income of $2.663 billion and earnings per share of $2.45. The 2007 and 2006 reported results include all charges listed in the reconciliation table below.

Full-Year 2007 Pro Forma Adjusted Results

Worldwide pro forma sales for the full-year 2007 were $18.706 billion, an increase of 14 percent compared with 2006. Worldwide pro forma
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement
2. Lilly Announces Dividend Increase
3. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
4. International Federation-Lilly Agreement Will Allow Significant Increase in MDR-TB Programmes
5. JDRF and Lilly partner to fund research to identify beta cell biomarkers
6. The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa
7. Lilly Contributes $10.8 Million to United Way Annual Campaign
8. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
9. Lilly Sets Date and Time for American Heart Association Conference Call
10. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
11. Eli Lilly and Company Aids California Recovery Effort
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 “Have you recently been involved ... and personal injury lawyer serving the greater Seattle area. “Are ... so, then keep reading . , In a recently ... in an auto accident can use to see if they ... a personal injury insurance claim will allow an individual to ...
(Date:8/20/2014)... The “Human Insulin Market by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2019” provides a detailed ... market trends,and strategies impacting the global human insulin ... the revenue and share analysis. , Browse 110 ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Mixberry Media ... speech-enable their websites and create a new source of ... consume content by listening to a narration of their ... reader genders and languages. Users can now multitask: ... social networks, while consuming content. , Mixberry ...
(Date:8/20/2014)... August 20, 2014 Over 31 million Americans ... of Disease, low back pain is the single leading cause ... reasons for missed work. Americans spend at least $50 billion ... Most cases of back pain are not due to organic ... , For example, Pete, a busy accountant, had little time ...
(Date:8/19/2014)... in Houston, Texas, is pleased to announce it is now ... with old fillings that need replacing, will benefit from the ... teeth. , From now on any cavities will be repaired ... amalgam free. Even though amalgam fillings have been deemed as ... children over the age of six, they do contain mercury ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... New Rochelle, NY, August 6, 2009The more time college ... to feel jealous toward their romantic partners, leading to ... will further fuel their jealousy, in an escalating cycle ... in CyberPsychology & Behavior , a peer-reviewed journal ...
... Gene signature detects differences in viral, bacterial infections, ... -- A genomic "signature" in blood appears able to ... viruses, such as the cold or flu, even before ... volunteers who were infected with either a live cold ...
... , , , ... Board: PSTX) today announced record quarterly revenues. , , ... Steven H. Kane, Chief Executive Officer of Patient Safety Technologies. ... adopting the Safety Sponge((TM)) System as the solution to the problem ...
... SOUTH PASADENA, Calif., Aug. 6 California Cancer ... center in South Pasadena. The 22,000 s.f. facility, operating under ... in medical, surgical and radiation oncology. In addition, ... San Gabriel Valley to offer RapidArc((TM)), a new and highly ...
... STAMFORD, Conn., Aug. 6 The Purdue Products L.P. ... the National Association of Chain Drug Stores (NACDS) 2009 Marketplace Conference, ... and the primary ingredient is the deseeded pod of the senna ... ) , , "We,ve always ...
... , Report Shows That Making Americans ... , , SAN DIEGO, Aug. 6 As ... decline in public support for health reform efforts, new research shows ... moving the reform needle. , , The ...
Cached Medicine News:Health News:Does Facebook usage contribute to jealousy in relationships? 2Health News:Cold, Flu or Pneumonia? Answer May Lie in Blood Test 2Health News:Patient Safety Technologies Reports Second Quarter Results 2Health News:Patient Safety Technologies Reports Second Quarter Results 3Health News:Patient Safety Technologies Reports Second Quarter Results 4Health News:Patient Safety Technologies Reports Second Quarter Results 5Health News:Patient Safety Technologies Reports Second Quarter Results 6Health News:Patient Safety Technologies Reports Second Quarter Results 7Health News:California Cancer Specialists Medical Group, Inc. Opens Outpatient Cancer Center in South Pasadena, Calif., With Renowned Medical Staff, State-of-the-Art Technology 2Health News:Senokot(R) Tablets Undergo a Natural Makeover 2Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 2Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 3Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 4Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 5Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 6
(Date:8/19/2014)... -- Talyst, a market leader in pharmacy automation and ... Summer Conference in Las Vegas, NV. ... products and services.   Talyst is the ... customers with a variety of software and services. Talyst ... solution, AutoSplit® Contract Pharmacy and 340B Compliance Services. AutoSplit ...
(Date:8/19/2014)... , Aug. 19, 2014  As power morcellator ... country, Bernstein Liebhard LLP notes that women in ... between a number of options that do not ... instrument. According to a report published by The ... these options include a mini-laparotomy and vaginal hysterectomy. ...
(Date:8/19/2014)... RIDGEFIELD, Conn. , Aug. 19, 2014 /PRNewswire/ ... and Drug Administration (FDA) accepted for review the ... (FDC) of tiotropium and olodaterol delivered via the ... of long-term, once-daily maintenance treatment of airflow obstruction ... including chronic bronchitis and/or emphysema. Tiotropium + olodaterol ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Cardiovascular Devices: Technologies ... , Offer a comprehensive view of the cardiovascular devices ... of the major types of cardiovascular diagnostic equipment, including ...
... , ... new market research report is available in its catalogue: ... Trends , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The ... a flurry of activity with pharmaceutical companies adding chiral ...
Cached Medicine Technology:Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 2Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 3Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 4Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 5Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 6Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 7Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 8Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 9Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 10Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 11Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 12Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5
... provides the most useful measurement for ... states. It is the preferred diagnostic ... patients who have experienced changes in ... dehydration. It is also used to ...
... HemoCue Hemoglobin Test Systems ... reliable quantitative hemoglobin results ... as a large hematology ... consists of either the ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: